Stocks scoring 25–45 beat the S&P 500
45.3% of the time over the next three months, since 2015.
How we measured this →
8
hedge funds
hold it · 4 new, 2 added, 1 trimmed
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$10.2B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGM
About APOGEE THERAPEUTICS INC
Apogee Therapeutics, Inc. develops and commercializes biologic therapies for immunological and inflammatory (I&I) diseases for patients and caregivers. The company's pipeline includes products, such as ZUMILOKIBART (APG777), a monoclonal antibody for atopic dermatitis, asthma, and eosinophilic esophagitis; APG990, a monoclonal antibody targeting OX40L; APG808, an antibody targeting IL-4Ra for chronic obstructive pulmonary disease and asthma; APG333, a half-life extended TSLP antibody; APG279, a combination therapy for atopic dermatitis; and APG273 for asthma and COPD. It also provides…
Who's behind the signal
Every informed buyer we can see on APGE, across all three feeds.
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
APOGEE THERAPEUTICS INC isn't in the top-10 model right now, but 8 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
8
Investors
4
New positions
2
Increasing
1
Decreasing
1
Unchanged
Price History
Loading price data...
Ctrl/⌘ + scroll or pinch to zoom · drag to measure · double-click to resetPinch to zoom · drag sideways to move through time
Return: High: Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
How much of each investor's portfolio is allocated to APOGEE THERAPEUTICS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell APOGEE THERAPEUTICS INC or any security.